key: cord-1003585-bsdeab7a authors: Burke, L.; Littlewood, E.; Gascoyne, S.; McMillan, D.; Chew-Graham, C. A.; Bailey, D.; Sloan, C.; Fairhurst, C.; Baird, K.; Hewitt, C.; Henry, A.; Ryde, E.; Shearsmith, L.; Coventry, P.; Crosland, S.; Newbronner, E.; Traviss-Turner, G.; Woodhouse, R.; Clegg, A.; Gentry, T.; Hill, A.; Lovell, K.; Dexter Smith, S.; Webster, J.; Ekers, D.; Gilbody, S. title: Behavioural Activation for Social IsoLation (BASIL+) trial (Behavioural activation to mitigate depression and loneliness among older people with long-term conditions): Protocol for a fully-powered pragmatic randomised controlled trial date: 2022-02-01 journal: nan DOI: 10.1101/2022.01.29.22270065 sha: 71811c1c899d2be14e5b3647f0b4f645876374fc doc_id: 1003585 cord_uid: bsdeab7a Abstract Introduction Depression is a leading mental health problem worldwide. People with long-term conditions are at increased risk of experiencing depression. The COVID-19 pandemic led to strict social restrictions being imposed across the UK population. Social isolation can have negative consequences on the physical and mental wellbeing of older adults. In the Behavioural Activation in Social IsoLation (BASIL + ) trial we will test whether a brief psychological intervention (based on Behavioural Activation), delivered remotely, can mitigate depression and loneliness in older adults with long-term conditions during isolation. Methods We will conduct a two-arm, parallel-group, randomised controlled trial across several research sites, to evaluate the clinical and cost-effectiveness of the BASIL + intervention. Participants will be recruited via participating general practices across England and Wales. Participants must be aged [≥]65 with two or more long-term conditions, or a condition that may indicate they are within a clinically extremely vulnerable group in relation to COVID-19, and have scored [≥]5 on the Patient Health Questionnaire (PHQ9), to be eligible for inclusion. Randomisation will be 1:1, stratified by research site. Intervention participants will receive up to eight intervention sessions delivered remotely by trained BASIL + Support Workers and supported by a self-help booklet. Control participants will receive usual care, with additional signposting to reputable sources of self-help and information, including advice on keeping mentally and physically well. A qualitative process evaluation will also be undertaken to explore the acceptability of the BASIL + intervention, as well as barriers and enablers to integrating the intervention into participants existing health and care support, and the impact of the intervention on participants mood and general wellbeing in the context of the COVID-19 restrictions. Semi-structured interviews will be conducted with intervention participants, participants caregivers/supportive others and BASIL + Support Workers. Outcome data will be collected at one, three, and 12 months post-randomisation. Clinical and cost-effectiveness will be evaluated. The primary outcome is depressive symptoms at the three-month follow up, measured by the PHQ9. Secondary outcomes include loneliness, social isolation, anxiety, quality of life, and a bespoke health services use questionnaire. Discussion This study is the first large-scale trial evaluating a brief Behavioural Activation intervention in this population, and builds upon the results of a successful external pilot trial. Trial Registration ClinicalTrials.Gov identifier ISRCTN63034289, registered on 5th February 2021. 116 Outcome data will be collected at one, three, and 12 months post-randomisation. Clinical and cost-117 effectiveness will be evaluated. The primary outcome is depressive symptoms at the three-month 118 follow up, measured by the PHQ9. Secondary outcomes include loneliness, social isolation, anxiety, disruption. This rapid change to social norms increased isolation leading to loneliness and 168 depression, which are known factors in the development of poorer mental health outcomes [12] . Existing research supports these reports, highlighting how social isolation has a disproportionate 170 effect on the physical and mental wellbeing of older adults [13, 14] . Loneliness is also considered a 171 significant public health concern in those aged 60 years and over, with evidence showing a link 172 between persistent loneliness and increased healthcare utilisation, regardless of health status [13] . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint rates. The schedule of enrolment, interventions and assessments is shown in Figure 1 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Identified potential participants will receive a study information pack (containing a practice letter-281 headed invitation letter, Participant Information Sheet and an example consent form) and a text 282 message about BASIL + (where possible) via their GP practice. Patients will be given the option to 283 complete an online consent form (via a link provided in the PIS, mirroring the example consent form 284 patients receive), or to contact the study team directly. Extended GP practice teams will contact the 285 remaining potential participants by telephone to determine interest in the study. Verbal permission 286 to pass on their contact details (permission to contact (PTC)) to the local BASIL + study team will be 287 obtained from interested patients and recorded. A BASIL + study researcher will then make contact via telephone (or video call using an appropriate 290 online platform) to discuss the study, answer any questions and determine eligibility. Where 291 patients are eligible and wish to participate, informed consent will be obtained (where online 292 consent has not already been provided). In response to the need to deliver the trial remotely, the . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. informed consent process will involve taking consent verbally. Participants will be directed to the 294 example consent form provided in the study information pack; the a researcher will read out each of 295 the consent statements, and request that the participant respond to confirm whether they agree or 296 disagree with the statement, and creating a written record of their responses. Once informed 297 consent has been confirmed, the baseline questionnaire will then be completed over the telephone 298 with a researcher (either immediately following confirmation of eligibility or at a later date, in line 299 with participant preference, and ideally within one week). Following baseline questionnaire completion, eligible and consenting participants will be 303 randomised 1:1 to either receive the intervention (BA) or usual care with signposting information. Randomisation will take place via a secure online randomisation service provided by the York Trials is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; https://doi.org/10.1101/2022.01.29.22270065 doi: medRxiv preprint minor design and wording changes to the self-help booklet). All sessions will be delivered remotely, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; https://doi.org/10.1101/2022.01.29.22270065 doi: medRxiv preprint Where data will be stored at non-NHS sites, the process for secure data storage will be reviewed and 397 approved by the trial Sponsor. All data will be stored securely in line with GCP and GDPR guidance. Access to participant data will be restricted according to researcher role. Participant confidentiality 399 will be maintained at all times unless significant risk to self or others is identified. 402 Relying on a text-heavy PIS has become the norm for many trials. approx.) will be randomised 1:1 using simple randomisation to either the SWAT intervention group 411 (potential participants receive PIS as usual, and infographic) or the SWAT control group (potential 412 participants receive PIS as usual, and no infographic). Generation of the SWAT allocation sequence 413 will be undertaken independently by a statistician at YTU not involved with the BASIL + recruitment 414 process. Study sites will be blind to SWAT group allocation. The primary outcome of the embedded SWAT will be the participant recruitment rate into the BASIL + 417 trial. Secondary outcomes will be i) participant response rate in terms of expressions of interest in 418 BASIL+ (permission to contacts received, direct participant contacts, or participant completion of the 419 online consent form -see recruitment section above), and ii) retention in BASIL+ as measured by 420 response to the three month post-randomisation participant questionnaire. . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; https://doi.org/10.1101/2022.01.29.22270065 doi: medRxiv preprint The proportion of participants randomised into the BASIL + trial will be compared between the SWAT 423 groups using a logistic regression model, adjusting for trial site as a random effect. The secondary 424 outcomes will be similarly analysed; the model for response rate at the three-month follow-up will 425 also include a covariate for BASIL+ allocation (intervention/usual care/not randomised is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint intention to treat basis, using two-sided statistical tests at the 5% significance level, using Stata v17 460 or later. The statistician will not be blinded to treatment allocation. The flow of participants through the trial will be detailed in a CONSORT diagram [ Figure 2 ]. The 463 number of individuals screened, eligible and randomised will be presented, with reasons for non-464 participation provided where available. Intervention adherence will be recorded and reported, 465 including the number of sessions completed. The number of participants withdrawing from the 466 intervention and/or the trial and any reasons for withdrawal will be summarised by trial arm. Participant baseline data will be summarised descriptively by trial arm, for all randomised 469 participants and for all who are included in the primary outcome analysis. No formal statistical 470 comparisons will be undertaken on baseline data. Continuous measures will be reported as means 471 and SD, while the categorical data will be reported as counts and percentages. . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 The primary outcome (PHQ9) will be analysed using a linear mixed model, incorporating data from 474 all post-randomisation follow-up time points (one, three and 12 months). The model will include 475 time, trial arm, an arm-by-time interaction, and baseline PHQ-9 score as fixed effects, with 476 participant nested within site as random effects. The model will provide an overall treatment effect 477 over time as well as estimates at individual time points, which will be reported as mean differences, 478 95% confidence intervals and p-values. The primary time-point of interest is pre-specified at three 479 months. intervention and health service use will be calculated using a bottom-up costing approach. Resources used to deliver the intervention will be obtained from the study team, whereas health 495 and social service resource use will be measured using a brief, tailored resource-use questionnaire, 496 developed based on the questionnaire used in the BASIL C-19 pilot study [23] . Unit costs of health 497 and social service use will be obtained from the UK national reference costs [47] and the Unit Costs 498 of Health and Social Care report [48] . Cost of other professional support will be estimated from . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; relevant salary scales and published reports/literature. Uncertainty around the incremental cost-500 effectiveness ratios (ICER) will be captured using non-parametric bootstrapping technique, and the 501 results will be presented in the conventional form of a cost-effectiveness acceptability curve (CEAC). Sensitivity analyses will be conducted to assess the impact of using SF-12v2 to measure QALYs and 503 the impact of including costs of informal care and other additional support. Qualitative process evaluation 506 The qualitative process evaluation will further explore the acceptability of the intervention, including 507 important elements of the intervention and mode of delivery, barriers and enablers to integrating 508 the intervention into participants' existing health and care support, and the impact of the 509 intervention on participants' mood and general wellbeing in the context of the COVID-19 510 restrictions. Semi-structured interviews will be undertaken with samples of study participants, BSWs 511 and caregivers/supportive others (where they have been involved in the intervention). Interviews will be conducted with 15-20 participants who complete the intervention ("completers"), 514 and up to 10 participants who were offered the intervention but who did not engage with or who 515 'dropped out' of the intervention. Up to 10 interviews will also be conducted with informal 516 caregivers/supportive others. All participant and caregiver interviews will take place after the 517 primary outcome has been completed. Interviews will be conducted with up to 20 BSWs and will explore barriers and facilitators to delivery 520 of the intervention and how the intervention might be integrated within health care settings. In 521 order to assist with maximum variation in the experiences of the BSWs interviewed, factors such as 522 intervention site location and demographic factors (such as job role, age and ethnicity) will be used 523 to support selection for interview. . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Interview topic guides will vary by participant group and will be modified iteratively as interviews 526 and analyses progress. All interviews will last up to approximately 30-45 minutes and will be 527 conducted over the telephone or a virtual platform. Study participants provide consent to taking part in a qualitative interview as part of a set of optional 530 consent statements (with form part of the trial consent form) upon entry to BASIL+. BSWs will obtain verbal permission from interested caregivers/supportive others for the BASIL + study 532 team to send them (post/email) a study information pack (containing an invitation letter, participant 533 information sheet and example consent form) followed by telephone contact from the study team to 534 discuss the study. For caregivers/supportive others who agree to take part in an interview, verbal 535 consent will be taken (and audio recorded) prior to the interview. BSWs will receive a study information pack (containing an invitation letter, information sheet and 538 example consent form) following BSW training. They will be invited to complete an online consent 539 form or to contact the qualitative study team directly to indicate their interest in taking part in an 540 interview. All interviews will be digitally-recorded (with participant consent), anonymised and transcribed, the 543 transcripts forming the data for analysis. Verbal consent for interview participation will be taken 544 (and recorded) before the interview commences. An initial thematic analysis will be conducted. Coding will be undertaken independently by members of the qualitative research team with 546 meetings to ensure emerging codes remain grounded in the original data. A framework approach 547 [49, 50] will be used to analyse the data, sensitised by the Normalisation Process Theory (NPT) [51] 548 to explore barriers and facilitators to rapid implementation of the BASIL + intervention into routine 549 practice. . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; https://doi.org/10.1101/2022.01.29.22270065 doi: medRxiv preprint 603 dignity of the participant as reflected in the 1996 version of the Helsinki Declaration. In order to 604 protect the study participants, the following provisions will be made/upheld; the study has been 605 designed to minimise pain, discomfort and fear and any foreseeable risk in relation to the 606 experiences/treatments involved, the explicit wishes of the participant will be respected including 607 the right to withdraw from the study at any time, the interest of the patient will prevail over those of 608 science and society, provision will be made for indemnity by the investigator and sponsor. Patients 609 will not be denied any form of care that is currently available in the NHS by participating in the 610 study. 612 Protocol amendments will be managed via the Health Research Authority, Research Ethics 613 Committee and sponsor approvals process during the study. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; https://doi.org/10.1101/2022.01.29.22270065 doi: medRxiv preprint Judith Webster, David Ekers, Elizabeth Newbronner, Claire Sloan 651 652 Competing interests 653 We have read the journal's policy and the authors of this manuscript have the following competing 654 interests. . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; https://doi.org/10. 1101 /2022 Simon 631 Gilbody Lauren Burke 640 Validation: Caroline Fairhurst References 681 1. Long-term conditions and multi-morbidity [Internet]. The King's Fund Multi-morbidity: clinical assessment and management. 2016. 688 4. World Health Organization. Depression Global burden of disease 691 attributable to mental and substance use disorders: findings from the Global Burden of Disease Study Does depression predict 694 the use of urgent and unscheduled care by people with long term conditions? A systematic review with meta-695 analysis Common patterns of 697 morbidity and multi-morbidity and their impact on health-related quality of life: evidence from a national 698 survey Five year forward view Coronavirus and shielding of clinically extremely vulnerable people in England -Office for National 701 Impact of COVID-19 on 705 loneliness, mental health, and health service utilisation: a prospective cohort study of older adults with 706 multimorbidity in primary care Effects of the COVID-19 708 pandemic on primary care-recorded mental illness and self-harm episodes in the UK: a population-based 709 cohort study. The Lancet Public Health Associations of social isolation with anxiety and depression during the early COVID-19 pandemic: a survey of 712 older adults in London, UK. Frontiers in Psychiatry Social disconnectedness, 714 perceived isolation, and symptoms of depression and anxiety among older Americans (NSHAP): a longitudinal 715 mediation analysis. The Lancet Public Health Loneliness as a public health issue: the impact of loneliness on 717 health care utilization among older adults. American journal of public health Loneliness is strongly linked to depression among older adults, a long term study 719 suggests A life less lonely: the 721 state of the art in interventions to reduce loneliness in people with mental health problems. Social psychiatry 722 and psychiatric epidemiology The effectiveness of 724 interventions for reducing subjective and objective social isolation among people with mental health 725 problems: a systematic review. Social psychiatry and psychiatric epidemiology The Community Navigator Study: Results from a feasibility randomised controlled trial 728 of a programme to reduce loneliness for people with complex anxiety or depression. Plos one Cognitive or behavioural interventions (or both) to prevent or mitigate loneliness in adolescents, 732 adults, and older adults. Cochrane database of systematic reviews (Online) Timely insights into the treatment of social disconnection in lonely Behavioural activation for 736 depression; an update of meta-analysis of effectiveness and sub group analysis. PloS one Collaborative care for 739 depression and anxiety problems Behavioural activation to prevent depression and loneliness among socially 742 isolated older people with long-term conditions: The BASIL COVID-19 pilot randomised controlled trial. PLoS 743 Medicine Effects of the COVID-19 pandemic on primary care-recorded mental illness and self-harm episodes in the UK: a 746 population-based cohort study. The Lancet Public Health Mental health and well-being during the COVID-19 pandemic: longitudinal 749 analyses of adults in the UK COVID-19 Mental Health & Wellbeing study. The British Journal of Psychiatry London: 754 Department of Health; 2012. 755 28. NHS Digital. The Quality and Outcomes Framework 2020 The PHQ-9: A new depression and diagnostic severity measure The short-form version of the Depression Anxiety Stress Scales Construct validity and normative data in a large non-clinical sample COVID-19: guidance for the public on mental health and wellbeing. Advice and 764 information on how to look after your mental health and wellbeing during the coronavirus (COVID-19) 765 outbreak: Public Health England Staying safe and well 2020 The development of a Rasch-type loneliness scale Assessing social networks among elderly populations. Family and community health A Brief Measure for Assessing Generalized Anxiety 775 Disorder: The GAD-7 A 12-Item Short-Form Health Survey: construction of 777 scales and preliminary tests of reliability and validity EuroQol: A new Instrument for the measurement of Health Related Quality of Life Automated pictographic 781 illustration of discharge instructions with Glyph: impact on patient recall and satisfaction Trial of infographics in Northern Ireland 784 (TINI): Preliminary evaluation and results of a randomized controlled trial comparing infographics with text. 785 Cogent medicine No difference in 787 knowledge obtained from infographic or plain language summary of a Cochrane systematic review: three 788 randomized controlled trials Monitoring depression treatment outcomes Practical help for specifying the target difference in sample size calculations for RCTs: 793 the DELTA2 five-stage study, including a workshop. Health technology assessment Effect of collaborative care vs usual care on depressive symptoms in older adults with 796 subthreshold depression: the CASPER randomized clinical trial Collaborative care for depression: a cumulative 798 meta-analysis and review of longer-term outcomes. Archives of internal medicine Methods for the Economic Evaluation of Health Care Programmes Ranking costs and outcomes of health care alternatives. Health Status and 802 Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation NHS Improvement. National Cost Collection Unit costs of health and social care 2019. Canterbury: University of Kent Using the framework method for the analysis of 807 qualitative data in multi-disciplinary health research. BMC medical research methodology Qualitative data analysis for applied policy research Implementing, embedding, and integrating practices: an outline of normalization 811 process theory Effect of collaborative care vs usual care on depressive symptoms in older adults with 814 subthreshold depression: the CASPER randomized clinical trial The effectiveness of psychological 816 interventions for loneliness: A systematic review and meta-analysis Cognitive or behavioural 818 interventions (or both) to prevent or mitigate loneliness in adolescents, adults, and older adults . CC-BY 4.0 International license It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted February 1, 2022. ; https://doi.org/10.1101/2022.01.29.22270065 doi: medRxiv preprint